FIELD: biotechnology.
SUBSTANCE: invention relates to the field of biotechnology, in particular to an isolated chimeric antigen receptor (hereinafter – CAR), which binds to BCMA, as well as to an isolated nucleic acid molecule encoding it. A domain binding BCMA is also disclosed. The invention also relates to a cell and a vector containing the above-mentioned nucleic acid molecule.
EFFECT: invention is effective for provision of antitumor immunity, as well as for treatment of a subject, which has a disease associated with BCMA expression.
57 cl, 3 dwg, 18 tbl, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| TREATMENT OF MALIGNANT NEOPLASM USING HUMANIZED CHIMERIC ANTIGEN RECEPTOR AGAINST BCMA | 2015 |
|
RU2751660C2 |
| CHIMERIC ANTIGEN RECEPTORS AND WAYS OF USE THEREOF | 2020 |
|
RU2841244C2 |
| METHODS OF PRODUCING CELLS EXPRESSING CHIMERIC ANTIGEN RECEPTOR | 2019 |
|
RU2822196C2 |
| TYPES OF COMBINATION THERAPY USING CHIMERIC ANTIGEN RECEPTORS AND PD-1 INHIBITORS | 2017 |
|
RU2809160C2 |
| TREATING CANCER USING CHIMERIC ANTIGEN-SPECIFIC RECEPTOR BASED ON HUMANIZED ANTI-EGFRvIII ANTIBODY | 2014 |
|
RU2831418C2 |
| CHIMERIC HUMAN MESOTHELIOGEN ANTIGEN RECEPTORS AND USE THEREOF | 2014 |
|
RU2714902C2 |
| CHIMERIC ANTIGENIC (CAR) RECEPTOR AGAINST CD123 FOR USE IN TREATING MALIGNANT TUMORS | 2015 |
|
RU2724999C2 |
| METHODS FOR PRODUCING CELLS EXPRESSING CHIMERIC ANTIGEN RECEPTOR | 2015 |
|
RU2751362C2 |
| TREATING CANCER USING A CHIMERIC ANTIGENIC CLL-1 RECEPTOR | 2015 |
|
RU2741120C2 |
| CHIMERIC ANTIGEN RECEPTORS FOR CANCER TREATMENT | 2017 |
|
RU2826270C2 |
